BidaskClub upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a sell rating to a hold rating in a research note published on Wednesday morning.

A number of other research analysts have also recently issued reports on the company. Zacks Investment Research cut Collegium Pharmaceutical from a hold rating to a sell rating in a report on Tuesday, July 10th. HC Wainwright reissued a buy rating on shares of Collegium Pharmaceutical in a report on Monday, September 17th. Cantor Fitzgerald cut their price objective on Collegium Pharmaceutical from $40.00 to $35.00 and set an overweight rating for the company in a report on Thursday, August 9th. Janney Montgomery Scott set a $27.00 price objective on Collegium Pharmaceutical and gave the company a buy rating in a report on Monday, August 6th. Finally, Piper Jaffray Companies set a $34.00 price objective on Collegium Pharmaceutical and gave the company a buy rating in a report on Wednesday, July 11th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Collegium Pharmaceutical has an average rating of Buy and an average target price of $31.71.

Shares of NASDAQ COLL traded down $0.07 during midday trading on Wednesday, reaching $16.95. 311,040 shares of the company traded hands, compared to its average volume of 527,767. The stock has a market cap of $489.69 million, a PE ratio of -6.86 and a beta of 0.43. Collegium Pharmaceutical has a 12 month low of $9.01 and a 12 month high of $29.90. The company has a debt-to-equity ratio of 3.94, a quick ratio of 0.78 and a current ratio of 0.82.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.02. The company had revenue of $73.10 million during the quarter, compared to analysts’ expectations of $72.21 million. Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. Collegium Pharmaceutical’s revenue was up 1930.6% on a year-over-year basis. Analysts predict that Collegium Pharmaceutical will post -1.49 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in COLL. Millennium Management LLC raised its holdings in shares of Collegium Pharmaceutical by 1,171.8% in the second quarter. Millennium Management LLC now owns 361,035 shares of the specialty pharmaceutical company’s stock valued at $8,611,000 after buying an additional 332,647 shares during the last quarter. Summit Trail Advisors LLC raised its holdings in shares of Collegium Pharmaceutical by 2,221.9% in the first quarter. Summit Trail Advisors LLC now owns 332,708 shares of the specialty pharmaceutical company’s stock valued at $333,000 after buying an additional 318,379 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Collegium Pharmaceutical by 13.8% in the second quarter. BlackRock Inc. now owns 2,252,273 shares of the specialty pharmaceutical company’s stock valued at $53,717,000 after buying an additional 272,302 shares during the last quarter. Macquarie Group Ltd. raised its holdings in shares of Collegium Pharmaceutical by 9.9% in the second quarter. Macquarie Group Ltd. now owns 2,588,356 shares of the specialty pharmaceutical company’s stock valued at $61,732,000 after buying an additional 233,598 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Collegium Pharmaceutical by 78.5% in the second quarter. Northern Trust Corp now owns 526,499 shares of the specialty pharmaceutical company’s stock valued at $12,557,000 after buying an additional 231,463 shares during the last quarter. 93.57% of the stock is owned by institutional investors and hedge funds.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Further Reading: The Role of a Fiduciary and Individual Investors

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.